Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick C Walsh

Showing results (111-120 of 361) with videos related to

Pageof 37
Sort By:
The Journal of Urology|April 13, 2012
Re: impact of meat consumption, preparation, and mutagens on aggressive prostate cancerPatrick C Walsh
The Journal of Urology|April 13, 2012
Re: vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Patrick C Walsh
The Journal of Urology|April 13, 2012
Re: outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA levelPatrick C Walsh
The Journal of Urology|June 12, 2012
Re: Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancerPatrick C Walsh
European Urology|July 27, 2019
Re: Association of Treatment with 5α-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate CancerPatrick C Walsh
The Journal of Urology|September 14, 2012
Re: An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancerPatrick C Walsh
The Journal of Urology|July 13, 2012
Re: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-upPatrick C Walsh
The Journal of Urology|July 13, 2012
Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancerPatrick C Walsh
The Journal of Urology|November 13, 2012
Re: Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPatrick C Walsh
The Journal of Urology|June 12, 2012
Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trialPatrick C Walsh
Pageof 37

Showing results (111-120 of 361) with videos related to

Sort By:
Pageof 37
The Journal of Urology|April 13, 2012
Re: impact of meat consumption, preparation, and mutagens on aggressive prostate cancerPatrick C Walsh
The Journal of Urology|April 13, 2012
Re: vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Patrick C Walsh
The Journal of Urology|April 13, 2012
Re: outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA levelPatrick C Walsh
The Journal of Urology|June 12, 2012
Re: Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancerPatrick C Walsh
European Urology|July 27, 2019
Re: Association of Treatment with 5α-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate CancerPatrick C Walsh
The Journal of Urology|September 14, 2012
Re: An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancerPatrick C Walsh
The Journal of Urology|July 13, 2012
Re: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-upPatrick C Walsh
The Journal of Urology|July 13, 2012
Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancerPatrick C Walsh
The Journal of Urology|November 13, 2012
Re: Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPatrick C Walsh
The Journal of Urology|June 12, 2012
Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trialPatrick C Walsh
Pageof 37